Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

By N. Katsumata, M. Yasuda, F. Takahashi, S. Isonishi, T. Jobo, D. Aoki, H. Tsuda, T. Sugiyama, S. Kodama, E. Kimura and 2 more. The Lancet, 2009

696 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Recent Progress in the Diagnosis and Treatment of Ovarian Cancer (2011, background): “03) when compared with standard therapy given every 3 weeks.(75) However, the dose-dense regimen is more toxic, and patients discontinued dose-dense paclitaxel therapy more often than did those receiving standard therapy.”
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Significant benefits in PFS and OS were seen at 3 years, and a recent update with longer followup has confirmed this benefit in women with small volume and >2 cm residual disease [44, 45].”
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. (2012, neutral): “The effects of experimental therapies, such as dose-dense therapy or treatment with DNA damage repair inhibitors, may similarly be evaluated in the context of gene expression signatures (39–41).”